TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer

Clinical trial NCT05188313 · RECRUITING

Trial details

NCT number: NCT05188313
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Esophageal Cancer Esophageal Adenocarcinoma

Start date: 2022-03-09
Primary completion: 2027-07-01
Enrollment: 376

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.